Enterprise Value
743.4M
Cash
377.6M
Avg Qtr Burn
-16.89M
Short % of Float
4.13%
Insider Ownership
14.08%
Institutional Own.
63.71%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bitopertin (GlyT1 inhibitor) Details erythropoietic porphyrias, X-linked protoporphyria | Phase 2 Data readout | |
Bitopertin (GlyT1 inhibitor) Details Rare genetic disease, Anemia | Phase 1/2 Data readout | |
DISC-0974 Details Myelofibrosis, Kidney disease, Anemia | Phase 1/2 Data readout | |
MWTX-003 (anti-TMPRSS6) Details Polycythemia vera | Phase 1 Initiation | |
GEM103 Details Age-related macular degeneration | Failed Discontinued | |
GEM103 Details Wet age-related macular degeneration , Age-related macular degeneration | Failed Discontinued |